Table 5. Summary of advantages and disadvantages of the selected panel of host cells for Leishmania susceptibility testing.
Cell type | Primary cells | Cell lines | ||||
---|---|---|---|---|---|---|
PEC | BMMφ | PBMC | THP-1 | J774 | RAW | |
Peritoneal macrophages | Myeloid progenitor cell derived |
Monocyte derived macrophages |
human
monocyte derived |
BALB/c
monocyte derived |
BALB/c macrophage derived | |
Source | Mouse | Mouse | Human blood | Commercial | Commercial | Commercial |
Cell stimulation | starch or thioglycollate | L929 supernatant GM-CSF | NA | PMA, VitD3 or RA | NA | NA |
Approximate yield | 107 cells/mouse | 107−108 cells/mouse | 105−106/mL (10% monocytes) |
NA | NA | NA |
Ethical concerns | +++ | +++ | ++ | - | - | - |
Biological relevance | ++ | ++ | +++ | - | - | - |
Receptivity for infection | +++ | +++ | + | + | ++ | ++ |
Intracellular multiplication | + | ++ | ++ | + | +/- | +/- |
Reproducibility | +++ | +++ | +/- | +/- | ++ | ++ |
Cost | ++ | ++ | +/- | +/- | +/- | +/- |
Consumables needed | + | ++ | +++ | + | + | + |
Technical complexity | + | +++ | ++ | +/- | +/- | +/- |